Kazia Therapeuti 424B Filings

Kazia Therapeutics Limited (KZIA) filed a prospectus supplement covering 232,956 American Depositary Shares (ADSs), representing 116,478,000 ordinary shares, and updating its F-1 prospectus with new clinical and preclinical information. The ADSs trade on Nasdaq under the symbol KZIA, with a last reported price of $13.77 per ADS on August 31, 2026.

Kazia reports preclinical data showing its lead asset paxalisib reduced tumor burden by 52% in microsatellite stable/proficient mismatch repair colorectal cancer, and in combination with pembrolizumab achieved a further 50% tumor volume reduction versus immunotherapy alone, with good tolerability. The company plans a five-arm Phase 2 trial in pre-treated MSS/pMMR metastatic colorectal cancer and expects enrollment to run through 2027. Separately, new preclinical data in HR+/HER2- breast cancer support expanding an ongoing TNBC trial into a three-arm study testing paxalisib plus fulvestrant, with or without palbociclib, versus standard of care, with first patient targeted by year-end 2026 and full enrollment by the end of 2027.

Kazia Therapeutics Limited (KZIA) filed a prospectus supplement for an existing Form F-1 registration covering 266,666 American Depositary Shares, each ADS representing in total 133,333,000 ordinary shares, and updated the document by attaching a new Form 6-K. The ADSs trade on Nasdaq under symbol KZIA, with a last reported price of $13.77 per ADS on August 31, 2026.

The attached Form 6-K includes two press releases on preclinical data for KZIA’s lead asset, paxalisib. In microsatellite stable / proficient mismatch repair colorectal cancer, paxalisib reduced tumor burden by 52%, and adding paxalisib to an immunotherapy reduced tumor volume by a further 50%, with treatment well tolerated; Kazia plans a five-arm Phase 2 trial in this setting with enrollment targeted for 2027. A second release reports preclinical data in HR+/HER2- breast cancer showing statistically significant antitumor activity and resensitization of CDK4/6 inhibitor-resistant tumors, supporting a three-arm expansion of an ongoing TNBC trial, with first patient expected by year-end 2026 and full enrollment by end of 2027. The company is also advancing biomarker programs and patent filings related to paxalisib and incorporates these disclosures by reference into multiple Form F-3 registration statements.

Kazia Therapeutics Limited (KZIA) filed a prospectus supplement to its Form F-1, referencing an offering of 95,110 American Depositary Shares (ADSs) representing 47,555,000 ordinary shares, and incorporating a new Form 6-K. The ADSs trade on Nasdaq under KZIA, with a last reported price of $13.77 per ADS on August 31, 2026.

The attached Form 6-K highlights preclinical data for lead asset paxalisib in difficult-to-treat cancers. In microsatellite stable / proficient mismatch repair colorectal cancer, paxalisib monotherapy reduced tumor burden by 52%, and adding paxalisib to an immunotherapy reduced tumor volume by a further 50%, with treatment described as well tolerated. Kazia plans a five-arm Phase 2 trial in this setting, targeting first patient enrollment in the first quarter of 2027 and full enrollment by year-end 2027.

Additional preclinical data in HR+/HER2- breast cancer showed statistically significant antitumor activity and resensitization of CDK4/6 inhibitor–resistant tumors to standard therapy. Kazia will expand an ongoing TNBC trial with a three-arm HR+/HER2- cohort, aiming for first patient by year-end 2026, full enrollment by end-2027, and a full data readout in 2028.

Kazia Therapeutics Limited (KZIA) filed a prospectus supplement to its Form F-1 prospectus covering 10,700,211 American Depositary Shares (ADSs), which represent 5,350,105,500 ordinary shares. The supplement incorporates a Form 6-K describing the launch of a new corporate website.

The company has changed its primary website to www.kaziatx.com, and prior references to www.kaziatherapeutics.com in its SEC filings should now be read as referring to the new URL. The ADSs trade on the Nasdaq Capital Market under the symbol KZIA, with a last reported sale price of $13.58 per ADS on August 28, 2026. The Form 6-K is also incorporated by reference into Kazia’s effective Form F-3 registration statements.

KAZIA THERAPEUTICS LTD (KZIA) filed a prospectus supplement to its Form F-1 registration statement describing an offering of 232,956 American Depositary Shares (ADSs), representing 116,478,000 ordinary shares

The attached Form 6-K reports that on August 28, 2026, Kazia launched a new corporate website at www.kaziatx.com, replacing prior references to www.kaziatherapeutics.com. The company states the site is intended to improve access to information on its business, products, services, clinical trials, and corporate developments. The Form 6-K is also incorporated by reference into three existing Form F-3 registration statements.

Kazia Therapeutics Limited (KZIA) has filed a prospectus supplement to its Form F-1 registration statement covering 266,666 American Depositary Shares (ADSs), each ADS representing 500 ordinary shares for a total of 133,333,000 ordinary shares. The supplement updates the existing prospectus by incorporating a Form 6-K dated August 31, 2026, which reports that on August 28, 2026 the company launched a new website at www.kaziatx.com, replacing prior references to www.kaziatherapeutics.com. The ADSs trade on the Nasdaq Capital Market under the symbol KZIA, and the last reported sale price on August 28, 2026 was $13.58 per ADS. The information in this Form 6-K is also incorporated by reference into Kazia’s registration statements on Form F-3 (File Nos. 333-276091, 333-281937 and 333-294392).

Kazia Therapeutics Limited (KZIA) filed a prospectus supplement under its Form F-1 registration statement to update the prospectus for an offering of 95,110 American Depositary Shares (ADSs), representing 47,555,000 ordinary shares. The supplement incorporates information from a Form 6-K dated August 31, 2026.

Kazia reports that on August 28, 2026 it launched a new website at www.kaziatx.com, and prior references to www.kaziatherapeutics.com in its SEC materials should be read to refer to the new URL. The ADSs trade on the Nasdaq Capital Market under the symbol KZIA, with a last reported sale price of $13.58 per ADS on August 28, 2026. The Form 6-K content is also incorporated by reference into Kazia’s Form F-3 registration statements (File Nos. 333-276091, 333-281937 and 333-294392).

Kazia Therapeutics Limited (KZIA) is conducting an underwritten shelf takedown offering of 2,276,800 ADSs (each ADS representing 500 ordinary shares) at $15.50 per ADS and accompanying warrants, plus Pre-Funded Warrants for 303,200 ADSs at $15.4999 each and accompanying warrants, for gross proceeds of about $40.0 million and estimated net proceeds of about $37.2 million.

Each ADS or Pre-Funded Warrant is sold together with Series A Warrants to purchase up to 2,243,478 ADSs at $17.825 and Series B Warrants to purchase up to 2,064,000 ADSs at $19.375. The warrants are immediately exercisable, have milestone-based/5‑year expirations, and will not be listed. If all Pre-Funded, Series A and Series B Warrants are exercised, ordinary shares outstanding would rise from 7.77 billion post-closing to 9.93 billion on a fully as‑adjusted basis.

Kazia expects to use the net proceeds primarily to advance its lead oncology drug paxalisib in multiple indications, including ongoing Phase 1b triple‑negative breast cancer (TNBC) work and new trials in HR+/HER2‑ breast cancer, colorectal cancer, and early-stage high‑risk TNBC, and for working capital. The company reports promising early TNBC data, including an 83% objective response rate in six evaluable patients, but emphasizes these results are preliminary. Auditors have included a going‑concern explanatory paragraph in prior financials.

Kazia Therapeutics Limited (KZIA) filed a prospectus supplement updating its at-the-market offering program of American Depositary Shares (ADSs) under its Form F-3 shelf. The company reduced the maximum aggregate offering price of ADSs that may be offered under its Sales Agreement with Leerink Partners LLC from $100,000,000 to $80,000,000, including ADSs previously sold. As of this supplement, Kazia has sold 510,000 ADSs for approximately $5,106,516 under the agreement. Each ADS represents 500 ordinary shares, and the ADSs trade on the Nasdaq Capital Market under the symbol KZIA, with a closing price of $16.90 per ADS on August 27, 2026.

Kazia Therapeutics Limited (KZIA) is conducting an underwritten public offering of American Depositary Shares (ADSs), each representing 500 ordinary shares, together with Series A and Series B warrants, and is also offering pre-funded warrants in lieu of ADSs to certain investors. Each ADS or pre-funded warrant is sold as a fixed package with one Series A and one Series B warrant; the warrants are immediately exercisable but will not be listed on an exchange, while the ADSs trade on Nasdaq under the symbol KZIA, which last closed at $14.60 per ADS on August 26, 2026.

As of December 31, 2025, Kazia had 5,020,465,734 ordinary shares outstanding, cash and cash equivalents of $69.46 million, and total equity of $46.47 million. Historical net tangible book value was $0.01 per ordinary share, or about $2.68 per ADS, indicating investors in this offering may experience dilution. The company qualifies as a foreign private issuer and reports under IFRS, with its books in Australian dollars.

Net proceeds are intended primarily to advance lead oncology candidate paxalisib, including an ongoing Phase 1b trial in advanced triple‑negative breast cancer (TNBC) with pembrolizumab and chemotherapy, and planned expansions into HR+/HER2‑ breast cancer, colorectal cancer and early-stage high-risk TNBC. In the TNBC program, six of six evaluable patients on paxalisib-based regimens showed clinical benefit, with an 83% objective response rate (one complete and four partial responses, one stable disease) and no paxalisib‑related serious adverse events reported, though the dataset remains small and early.

Kazia Therapeutics Limited (KZIA) filed a prospectus supplement relating to its Form F-1 registration, covering 10,700,211 American Depositary Shares (ADSs) representing 5,350,105,500 ordinary shares. The supplement attaches an August 27, 2026 Form 6-K with new clinical and corporate information.

Kazia reports early data for its lead drug paxalisib in Stage IV triple-negative breast cancer: all six evaluable patients achieved clinical benefit, with an 83% objective response rate (one complete and four partial responses) and one durable complete metabolic response ongoing since November 2025. Median reductions were 83% in circulating tumor cell clusters and 51% in terminally exhausted CD8+ T cells, with no paxalisib-related serious adverse events.

The investor presentation describes a broader oncology pipeline, including paxalisib in multiple solid tumors and preclinical PD-L1 degrader and SETDB1 programs. Kazia reports approximately US$46 million in cash and equivalents as of December 31, 2025, no debt, and about 14.1 million fully diluted ADSs, with funding expected to support planned operations into 2029, excluding additional or expanded trials.

Kazia Therapeutics Limited (KZIA) has filed a prospectus supplement covering 232,956 American Depositary Shares (ADSs) representing 116,478,000 ordinary shares, updating its existing Form F-1 prospectus with new August 27, 2026 disclosures. The ADSs trade on Nasdaq under the symbol KZIA, with a last reported price of $14.60 per ADS on August 26, 2026.

The update incorporates a Form 6-K that includes new clinical data for lead asset paxalisib in Stage IV triple-negative breast cancer (TNBC). In six evaluable patients, the company reports a 100% clinical benefit rate, with 5 of 6 patients (83%) achieving objective responses (one complete, four partial) and one patient achieving stable disease, alongside no paxalisib-related serious adverse events. Translational analyses showed median reductions of about 83% in circulating tumor cell clusters and 51% in terminally exhausted CD8+ T cells, while total CD8+ T-cell counts remained stable.

Kazia states it had approximately $46 million in cash and cash equivalents as of December 31, 2025, with no outstanding debt and about 14.1 million fully diluted ADSs outstanding, and that this cash is expected to fund planned operations into 2029, excluding additional or expanded trials. The supplement also furnishes an investor presentation describing paxalisib’s broader development in glioblastoma, other breast cancer subtypes and colorectal cancer, and preclinical programs NDL2 (PD-L1 degrader) and MSETC (SETDB1 inhibitor).

Kazia Therapeutics Limited (KZIA) filed a prospectus supplement covering 266,666 American Depositary Shares (ADSs), each ADS representing ordinary shares, and attached an August 27, 2026 Form 6-K with updated clinical and corporate information. The ADSs trade on Nasdaq under the symbol KZIA, with a last reported price of $14.60 per ADS on August 26, 2026.

The company reported early data for its lead drug paxalisib in six evaluable patients with Stage IV triple-negative breast cancer. All six achieved clinical benefit, with an objective response rate of 83% (one complete and four partial responses) and one remaining patient with stable disease. Across these patients, median reductions were 83% in circulating tumor cell clusters and 51% in terminally exhausted CD8+ T cells, while no treatment-related serious adverse events were observed. Kazia plans to complete enrollment in its ongoing Phase 1b TNBC study by July 2027 and to expand paxalisib development into HR+/HER2− breast cancer and pMMR colorectal cancer.

The investor presentation indicates cash and cash equivalents of about $46 million as of December 31, 2025, no outstanding debt, and approximately 14.1 million fully diluted ADSs outstanding. The company expects this cash to fund planned operations into 2029, excluding additional or expanded trials, and outlines intended use of offering proceeds to advance paxalisib trials and its preclinical PD‑L1 degrader (NDL2) and SETDB1 inhibitor (MSETC) programs.

KAZIA THERAPEUTICS LTD (KZIA) filed a prospectus supplement for an existing Form F-1 offering covering 95,110 American Depositary Shares (ADSs), each representing ordinary shares, and updating investors with new clinical and corporate information. The ADSs trade on Nasdaq under symbol KZIA; the last reported price was $14.60 per ADS on August 26, 2026.

The attached Form 6-K highlights early Phase 1b data for lead asset paxalisib in six evaluable patients with Stage IV triple-negative breast cancer, showing a 100% clinical benefit rate, including 1 complete and 4 partial responses, plus reductions in metastasis-associated circulating tumor cell clusters and terminally exhausted CD8+ T cells, with no paxalisib-related serious adverse events reported. Kazia also outlines broader development plans for paxalisib across glioblastoma, advanced breast cancer and pMMR colorectal cancer, and preclinical programs NDL2 and MSETC, alongside a capital position of approximately US$46 million in cash and cash equivalents and about 14.1 million fully diluted ADSs outstanding.

Kazia Therapeutics Limited filed a prospectus supplement covering 266,666 American Depositary Shares (ADSs), representing 133,333,000 ordinary shares, and updating its existing Form F-1 prospectus by incorporating a new Form 6-K.

The incorporated Form 6-K includes a press release describing a provisional patent application for a novel perioperative therapeutic strategy using paxalisib to prevent metastatic recurrence in high-risk early-stage triple-negative breast cancer. In a preclinical TNBC model, standard therapy followed by adjuvant paxalisib reduced residual disease and local recurrence by 95% and lung metastatic burden by 40%, while ex vivo studies showed 100% disruption of circulating tumor cell clusters. The company is evaluating expansion of paxalisib development into earlier-stage TNBC. The ADSs trade on Nasdaq under the symbol KZIA, with a last reported price of $12.21 per ADS on July 27, 2026.

Kazia Therapeutics Limited is updating its existing Form F-1 prospectus through a prospectus supplement covering 232,956 American Depositary Shares (ADSs), representing 116,478,000 ordinary shares. The ADSs trade on Nasdaq under “KZIA,” with a last reported price of $12.21 per ADS on July 27, 2026.

Through an attached Form 6-K, the company reports filing a provisional patent application for a novel perioperative strategy using its lead asset, paxalisib, aimed at preventing metastatic recurrence in high-risk early-stage triple-negative breast cancer. Preclinical perioperative studies showed a 95% reduction in residual disease and local recurrence and a 40% reduction in lung metastatic burden when standard therapy was followed by adjuvant paxalisib, while ex vivo studies showed 100% disruption of circulating tumor cell clusters.

Kazia Therapeutics Limited filed a prospectus supplement updating a Form F-1 registration covering 95,110 American Depositary Shares (ADSs), representing 47,555,000 ordinary shares. The supplement incorporates a July 28, 2026 report describing new scientific developments into the offering materials.

The company reports filing a provisional patent for a novel perioperative therapeutic strategy aimed at preventing metastatic recurrence in high-risk early-stage triple-negative breast cancer. In a TNBC preclinical model, standard treatment followed by adjuvant paxalisib reduced residual disease and local recurrence by 95% and lung metastatic burden by 40%. Ex vivo studies on patient tumor samples showed paxalisib fully disrupted (100%) circulating tumor cell clusters. These data, together with observations from an ongoing Phase Ib metastatic TNBC study, are presented as supporting further development of paxalisib across multiple disease stages.

Kazia Therapeutics Limited is updating an existing Form F-1 prospectus covering 10,700,211 American Depositary Shares (ADSs), each representing underlying ordinary shares, by incorporating a new Form 6-K filed on July 28, 2026. The ADSs trade on Nasdaq under the symbol KZIA, and the last reported price on July 27, 2026 was $12.21 per ADS.

The attached report describes a new provisional patent application for a novel therapeutic strategy aimed at preventing metastatic recurrence in high-risk early-stage triple-negative breast cancer using paxalisib. In a perioperative TNBC model, standard therapy followed by paxalisib reduced residual disease and local recurrence by 95% and lung metastatic burden by 40%, and ex vivo patient samples showed 100% disruption of circulating tumor cell clusters. These preclinical and translational findings, together with observations from an ongoing Phase Ib study in metastatic TNBC, are cited as support for broadening paxalisib development across multiple stages of disease.

Kazia Therapeutics files a prospectus supplement registering 10,700,211 American Depositary Shares, representing 5,350,105,500 ordinary shares. The supplement incorporates a Form 6-K furnished June 2, 2026, which discloses the appointment of James Levine as Chief Financial Officer, effective June 1, 2026.

Mr. Levine’s employment terms include an annual base salary of $475,000, an annual target bonus equal to 40% of base salary (prorated for 2026), and a proposed grant, subject to Board approval, of options over 200,000 ADSs with one-third vesting on commencement and the balance vesting in equal yearly installments. Severance and post-termination benefits are described in the Employment Agreement filed as Exhibit 10.1.

Kazia Therapeutics Limited files a prospectus supplement registering 232,956 American Depositary Shares. The supplement, dated June 2, 2026, incorporates a Form 6-K that announces the appointment of James Levine as Chief Financial Officer effective June 1, 2026, and summarizes his employment terms.

The prospectus supplement states the ADSs trade on Nasdaq under the symbol KZIA and notes a reported last sale price of $12.56 per ADS as of June 1, 2026. The Form 6-K discloses Mr. Levine’s US$475,000 base salary, a 40% target bonus (prorated for 2026), and a 200,000 ADS option grant subject to Board approval and vesting terms. Employment and severance provisions are summarized in the furnished Employment Agreement (Exhibit 10.1).

Kazia Therapeutics Limited files a prospectus supplement registering 266,666 American Depositary Shares (ADSs) as set forth on the prospectus supplement dated June 2, 2026. The supplement incorporates a Form 6-K reporting the appointment of James Levine as Chief Financial Officer, effective June 1, 2026, and summarizes his employment terms.

The prospectus supplement discloses that the ADSs trade on Nasdaq under the symbol KZIA and notes a last reported sale price of $12.56 per ADS on June 1, 2026. The Form 6-K describes Mr. Levine’s compensation package, including a $475,000 base salary, a 40% target bonus (prorated for 2026), and a proposed grant of 200,000 ADS options subject to Board approval and vesting conditions.

Kazia Therapeutics Limited files a prospectus supplement registering 95,110 American Depositary Shares (ADSs) representing 47,555,000 Ordinary Shares as described on the supplement cover. The supplement incorporates a Form 6-K dated June 2, 2026 and updates the Prospectus dated December 22, 2025.

The Form 6-K included in the supplement furnishes a press release announcing the appointment of James Levine as Chief Financial Officer effective June 1, 2026, and summarizes his employment terms: a $475,000 base salary, a 40% target bonus (prorated for 2026), and a proposed grant of 200,000 ADS options subject to Board approval and vesting terms. The ADSs trade on Nasdaq under the symbol KZIA.

Kazia Therapeutics is supplementing its registration materials to cover 232,956 American Depositary Shares, representing 116,478,000 Ordinary Shares. The supplement incorporates a May 26, 2026 Form 6-K announcing expansion of a Phase 1b paxalisib trial in advanced triple negative breast cancer: planned enrollment will increase from 12 to 36 patients to further assess safety, dose optimization and preliminary efficacy. The press release notes continued encouraging safety and tolerability and anticipates additional updates through 2026 into 2027.

Kazia Therapeutics Limited filed a prospectus supplement registering 95,110 American Depositary Shares representing 47,555,000 Ordinary Shares and furnished a Form 6-K attaching a May 26, 2026 press release. The release announces an expansion of its Phase 1b paxalisib trial in advanced triple negative breast cancer, increasing planned enrollment from 12 to 36 patients based on continued encouraging safety and tolerability data. The supplement updates the Prospectus dated December 22, 2025 and attaches the press release; the ADSs trade on Nasdaq under the symbol KZIA.

Kazia Therapeutics filed a prospectus supplement dated May 26, 2026 registering 10,700,211 American Depositary Shares representing 5,350,105,500 ordinary shares as part of its Form F-1 registration. The supplement incorporates a Form 6-K announcing an expansion of its ongoing Phase 1b trial of paxalisib in advanced triple negative breast cancer, increasing planned enrollment from 12 to 36 patients to further evaluate safety, dose optimization and preliminary efficacy. The ADSs trade on Nasdaq under the symbol KZIA, with a reported last sale price of $13.66 per ADS on May 22, 2026. Additional clinical updates are expected through 2026 and into 2027.

Kazia Therapeutics Limited files a prospectus supplement registering 266,666 American Depositary Shares representing 133,333,000 Ordinary Shares as part of its existing registration. The supplement attaches a Form 6-K disclosing an expansion of the ongoing Phase 1b paxalisib trial in advanced triple negative breast cancer, increasing planned enrollment from 12 to 36 patients. The ADSs trade on Nasdaq under the symbol KZIA; the last reported sale price was $13.66 per ADS on May 22, 2026.

Kazia Therapeutics Limited is supplementing its prospectus to register 232,956 American Depositary Shares representing 116,478,000 Ordinary Shares. The supplement incorporates a Form 6-K disclosing the appointment of Dr. Sudha Rao as Chief Scientific Officer, effective April 13, 2026.

Dr. Rao will serve part-time (three days per week) with a base salary of AUD$325,000, a target annual bonus of 40%, and a proposed grant of 250,000 ADS options (one-third vest at commencement, remainder in two equal annual installments). The employment agreement permits concurrent work with QIMR Berghofer Medical Research Institute.

Kazia Therapeutics Limited files a prospectus supplement registering 95,110 American Depositary Shares (ADS) representing 47,555,000 Ordinary Shares. The supplement incorporates a Form 6-K reporting the appointment of Dr. Sudha Rao as Chief Scientific Officer, effective April 13, 2026, and summarizes her employment terms.

The Form 6-K discloses Dr. Rao’s part‑time (three days/week) role with an annual base salary of AUD$325,000, a target annual performance bonus of 40% of base salary, and a proposed grant of 250,000 ADS options (subject to Board approval) with staggered vesting. The ADSs trade on Nasdaq under the symbol KZIA (last reported sale price $9.46 per ADS as of April 14, 2026).

Kazia Therapeutics Limited files a prospectus supplement registering 10,700,211 American Depositary Shares (ADS), representing 5,350,105,500 ordinary shares, and incorporates a Form 6-K dated April 15, 2026 into that prospectus supplement. The supplement updates the Prospectus dated December 23, 2025 and includes a Form 6-K disclosing the appointment of Dr. Sudha Rao as Chief Scientific Officer, effective April 13, 2026.

Under an employment agreement, Dr. Rao will work part-time (three days per week) with an annual base salary of AUD$325,000, a target annual performance bonus of 40% of base salary, and a proposed grant of 250,000 ADS options subject to approval by the Company’s Board of Directors, with one-third vesting at commencement and the remainder vesting in two equal annual installments.

Kazia Therapeutics filed a prospectus supplement and Form 6-K updating its Registration Statement and furnishing a press release announcing the appointment of Dr. Sudha Rao as Chief Scientific Officer, effective April 13, 2026. The supplement states 266,666 American Depositary Shares representing 133,333,000 Ordinary Shares. The Form 6-K describes Dr. Rao’s part-time employment (three days per week), an annual base salary of AUD$325,000, a target annual performance bonus of 40% of base salary, and a proposed grant of 250,000 ADS options (subject to Board approval) with one-third vesting on commencement and the remainder vesting in two equal annual installments.

Kazia Therapeutics Limited is registering 232,956 American Depositary Shares (ADSs) representing 116,478,000 Ordinary Shares under a prospectus supplement dated April 13, 2026. The company disclosed it entered a license and commercialisation agreement with QIMR Berghofer on April 10, 2026, under which Kazia obtained an exclusive worldwide license to a SETDB1-targeted epigenetic platform.

The agreement requires an upfront license payment of $1,390,000 payable within 15 business days of execution and a tiered revenue-sharing arrangement on commercialization revenue. The licensed program is in preclinical development; Kazia estimates combined costs of about $6 million over 18 months to advance the SETDB1 and PD-L1 degrader programs to IND readiness.

Kazia Therapeutics Limited files a prospectus supplement registering 95,110 American Depositary Shares representing 47,555,000 Ordinary Shares pursuant to the Registration Statement on Form F-1, as supplemented by a Form 6-K furnished April 13, 2026.

The April 10, 2026 Form 6-K discloses Kazia's entry into an exclusive, worldwide license with QIMR Berghofer for a SETDB1-targeted epigenetic platform. Under the Agreement Kazia will pay an upfront license fee of $1,390,000 and agreed revenue-sharing percentages on commercialization revenue; Kazia plans IND-enabling work and to use commercially reasonable efforts to develop at least one product under the license.

Kazia Therapeutics Limited files a prospectus supplement registering 266,666 American Depositary Shares representing 133,333,000 Ordinary Shares. The supplement incorporates a Form 6-K disclosing an exclusive, worldwide License and Commercialisation Agreement with QIMR Berghofer for a SETDB1-targeted epigenetic platform.

Under the agreement Kazia will pay an upfront license fee of $1,390,000 and a tiered revenue-sharing percentage on commercialization receipts; Kazia intends to advance the SETDB1 program in preclinical work toward IND-enabling studies in parallel with its PD-L1 degrader program.

Kazia Therapeutics Limited files a prospectus supplement registering 10,700,211 American Depositary Shares representing 5,350,105,500 ordinary shares in connection with its Form F-1 registration.

The supplement attaches a Form 6-K describing Kazia's April 10, 2026 license and commercialisation agreement with QIMR Berghofer, under which Kazia licensed a SETDB1-targeted epigenetic platform and agreed to pay an upfront license fee of $1,390,000. The Form 6-K and attached press release describe the licensed lead candidate MSETC, preclinical status, a projected $6 million combined cost to advance two preclinical programs to IND readiness over 18 months, and a tiered revenue-sharing structure with no clinical or regulatory milestone obligations.

Kazia Therapeutics Limited filed a prospectus supplement to update its Form F-1 registration for 95,110 American Depositary Shares representing 47,555,000 Ordinary Shares, referencing a Form 6-K dated March 31, 2026. The supplement attaches a March 27, 2026 investor presentation and fact sheet and notes a board change: Chairman Bryce Carmine resigned effective March 31, 2026, reducing the board from four to three directors. The company reported the re-election of Steven Coffey with 1,050,412,780 votes for.

Kazia Therapeutics Limited files a prospectus supplement registering 10,700,211 American Depositary Shares, representing 5,350,105,500 Ordinary Shares, and furnishes a Form 6-K dated March 31, 2026. The supplement attaches an investor presentation and fact sheet dated March 27, 2026 and notes the ADS last sale price of $7.31 per ADS.

The Form 6-K reports the resignation of Chairman Bryce Carmine effective March 31, 2026, a reduction in Board size from four to three directors, appointment of Ebru Davidson to the Audit, Risk and Governance Committee, and shareholder re-election of Steven Coffey at the AGM.

Kazia Therapeutics Limited filed a prospectus supplement updating its Form F-1 registration to reflect a Form 6-K furnished March 31, 2026. The supplement covers 266,666 ADSs representing 133,333,000 Ordinary Shares and states the ADSs trade on Nasdaq under the symbol KZIA. The company reported the March 25, 2026 Annual General Meeting approved the re-election of Steven Coffey with 1,050,412,780 votes for, and noted the resignation of Chairman Bryce Carmine effective March 31, 2026, reducing the Board from four to three directors.

Kazia Therapeutics Limited files a prospectus supplement registering 232,956 American Depositary Shares (ADSs). The supplement attaches a Form 6-K dated March 31, 2026 and updates the Prospectus dated December 23, 2025.

The Form 6-K discloses the resignation of Chairman Bryce Carmine effective March 31, 2026, the Board shrinking from four to three directors, appointment of Ebru Davidson to the Audit, Risk and Governance Committee, and AGM vote results re‑electing Steven Coffey (1,050,412,780 for; 3,637,588 against; 1,289,127 abstain). The ADSs trade on Nasdaq under symbol KZIA (last reported sale $7.31 per ADS).

Kazia Therapeutics Limited filed a prospectus supplement registering 10,700,211 American Depositary Shares (representing 5,350,105,500 ordinary shares) to update the Prospectus dated December 23, 2025.

The supplement incorporates a Form 6-K that attaches the Company’s half‑year report for the six months ended 31 December 2025, reporting a loss after tax of $12,552,490 and cash and cash equivalents of $69,459,980. The supplement notes the ADSs trade on Nasdaq under the symbol KZIA and references private placement activity, including a December PIPE with reported net proceeds of US$46,509,833.

Kazia Therapeutics Limited is registering 266,666 American Depositary Shares representing 133,333,000 ordinary shares.

This prospectus supplement (to the December 22, 2025 prospectus) incorporates a Form 6-K furnished on March 19, 2026 and discloses the company’s half-year results for the six months ended 31 December 2025. The half‑year report shows a loss after tax of $12,552,490 and cash and cash equivalents of $69,459,980 as of 31 December 2025. The report also describes two private placements during the period, including a December 2025 placement with net proceeds of approximately $46.5M and an earlier placement of approximately $2.0M. The ADSs trade on Nasdaq under the symbol KZIA; the last reported sale price on March 18, 2026 was $7.51 per ADS.

Kazia Therapeutics Limited filed a prospectus supplement registering 232,956 American Depositary Shares, representing 116,478,000 ordinary shares, as set out in a prospectus supplement dated March 19, 2026.

The half‑year report for the six months ended 31 December 2025 shows a loss after tax of $12,552,490 and cash and cash equivalents of $69,459,980. Directors state the financial statements are prepared on a going concern basis. The company completed a private placement in December 2025 with expected net proceeds of $46.5 million to support clinical programs including paxalisib.

Registration covers 95,110 American Depositary Shares representing 47,555,000 ordinary shares, as set forth in a prospectus supplement to the Form F-1.

This supplement incorporates a Form 6-K dated March 19, 2026 attaching the company’s half‑year report for the six months ended 31 December 2025. The half‑year report shows a loss after tax of $12,552,490 and cash and cash equivalents of $69,459,980 as at 31 December 2025. The report discloses recent capital raises, including a private placement with net proceeds of approximately $46,509,833 and material issuances of ordinary shares and pre‑funded warrants closed in December 2025.

Kazia Therapeutics Limited files a prospectus supplement covering 266,666 American Depositary Shares, representing 133,333,000 ordinary shares, and updates investors using a newly furnished Form 6-K.

The attached report highlights encouraging early results from an ongoing Phase 1b study of paxalisib in late-stage metastatic triple-negative breast cancer. Three patients treated with paxalisib-based regimens have shown meaningful clinical responses, including two partial responses in trial participants and one confirmed complete metabolic response in an expanded access patient.

Paxalisib in combination with pembrolizumab and chemotherapy has been generally well tolerated, with most adverse events deemed unlikely or unrelated to paxalisib and reported paxalisib-related events mainly mild to moderate. Kazia plans to activate additional clinical sites in 2026, aims to enroll twelve triple-negative breast cancer patients by the end of 2026, and anticipates topline data in early 2027.

Kazia Therapeutics Limited files a prospectus supplement covering 95,110 American Depositary Shares (ADSs), which represent 47,555,000 ordinary shares, to update its existing Form F‑1 prospectus with new clinical information from a recent Form 6‑K. The update centers on a Phase 1b study of paxalisib in late‑stage metastatic triple‑negative breast cancer (TNBC) in combination with pembrolizumab and chemotherapy.

In this program, three patients with metastatic TNBC treated with paxalisib‑based regimens have shown meaningful responses: two partial responses in trial participants and one confirmed complete metabolic response in a patient treated under an expanded access program. Paxalisib has been generally well tolerated, with most adverse events considered unlikely or unrelated to the drug and only expected, mainly mild to moderate, paxalisib‑related side effects reported at the 30 mg daily dose.

Kazia plans to activate two additional clinical sites by April 2026 and two more in mid‑2026, targeting enrollment of twelve TNBC patients by the end of 2026 and a topline data readout in early 2027, while continuing broader development of paxalisib and other oncology assets.

Kazia Therapeutics Limited supplements its prospectus covering 232,956 American Depositary Shares, each representing 500 ordinary shares, with a new clinical update on paxalisib in metastatic triple-negative breast cancer (TNBC). The attached Form 6-K details preliminary results from an ongoing Phase 1b study of paxalisib in combination with pembrolizumab and chemotherapy or with olaparib in advanced breast cancer. Three metastatic TNBC patients have shown meaningful responses: two partial responses in trial participants and one confirmed complete metabolic response in an expanded access patient, all remaining on treatment. Paxalisib has been generally well tolerated at a 30 mg daily dose, with mostly mild to moderate expected side effects and two serious adverse events reported as unrelated to paxalisib. Kazia plans to activate additional clinical sites in 2026, target enrollment of twelve TNBC patients by the end of 2026, and expects topline data in early 2027.

Kazia Therapeutics Limited has a prospectus supplement covering 10,700,211 American Depositary Shares, representing 5,350,105,500 ordinary shares, and uses it to incorporate a new clinical update into its existing Form F-1 prospectus. The supplement attaches a Form 6-K that reports preliminary results from an ongoing Phase 1b study of paxalisib in combination with pembrolizumab and chemotherapy in late-stage metastatic triple-negative breast cancer.

The company notes three meaningful clinical responses so far: two partial responses in trial participants and one confirmed complete metabolic response in a patient treated under an expanded access program. Paxalisib has been generally well tolerated with mostly mild to moderate expected side effects, and Kazia plans to activate additional clinical sites in 2026, complete enrollment of twelve TNBC patients by the end of 2026, and target a topline data readout in early 2027.

Kazia Therapeutics Limited is registering for resale up to 232,956 American Depositary Shares (ADSs), representing 116,478,000 ordinary shares, held by existing investors. These ADSs consist of ordinary shares and ADSs issuable upon exercise of pre-funded warrants originally sold in a prior private placement, and all sale proceeds will go to the selling shareholders, not the company.

Kazia is an oncology-focused biotech developing paxalisib for glioblastoma and other brain cancers, and EVT801 for solid tumors. In December 2025, the company completed a private placement of 4,530,854,000 ordinary shares and pre-funded warrants to purchase up to 938,490 ADSs, generating approximately $46.5 million in net proceeds, which management expects will fund operations into the second half of 2028. Nasdaq has also confirmed that Kazia’s ADSs remain in compliance with listing standards after a prior deficiency related to market value of listed securities.

Kazia Therapeutics Limited is updating a previously registered offering of 95,111 American Depositary Shares, representing 47,555,560 ordinary shares, via a prospectus supplement that incorporates its latest Form 6-K disclosure. The ADSs trade on Nasdaq under the symbol KZIA, and on November 17, 2025, the last reported sale price was $6.08 per ADS.

The attached Form 6-K explains that Kazia has not regained compliance with Nasdaq’s $35 million Market Value of Listed Securities requirement by the November 10, 2025 deadline. Nasdaq staff has issued a determination letter, and Kazia intends to request a hearing before a Nasdaq Hearings Panel, which will temporarily stay any suspension or delisting. The company plans to present a compliance plan at the hearing but cautions there is no assurance the Panel will accept it or that it will ultimately meet all Nasdaq listing standards.

Kazia Therapeutics Limited updates its prospectus covering 1,770,000 American Depositary Shares, representing 885,000,000 ordinary shares, by incorporating a new Form 6-K. The update explains that Nasdaq previously notified the company its Market Value of Listed Securities was below the required $35 million from March 28, 2025 to May 9, 2025, triggering a compliance period that ended on November 10, 2025. On November 12, 2025, Nasdaq staff determined Kazia had not regained compliance and indicated its securities are subject to suspension or delisting unless a hearing is requested. Kazia plans to request a hearing before a Nasdaq Hearings Panel to present a plan to regain and sustain compliance, but there is no assurance the panel will accept the plan or that compliance will be restored.